Yuhan Corp Preferred (000105) - Total Liabilities
Based on the latest financial reports, Yuhan Corp Preferred (000105) has total liabilities worth ₩936.71 Billion KRW (≈ $634.79 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Yuhan Corp Preferred (000105) long-term investment share to see how much of total assets are deployed in long-term investments.
Yuhan Corp Preferred - Total Liabilities Trend (2014–2025)
This chart illustrates how Yuhan Corp Preferred's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 000105 asset base.
Yuhan Corp Preferred Competitors by Total Liabilities
The table below lists competitors of Yuhan Corp Preferred ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BII Railway Transportation Technology Holdings Company Limited
F:CN6
|
Germany | €1.97 Billion |
|
SelfWealth Limited
AU:SWF
|
Australia | AU$344.06 Million |
|
Awilco LNG ASA
OL:ALNG
|
Norway | Nkr192.06 Million |
|
Peoplein Ltd
AU:PPE
|
Australia | AU$181.87 Million |
|
GSD Denizcilik Gayrimenkul Insaat Sanayi ve Ticaret AS
IS:GSDDE
|
Turkey | TL1.92 Billion |
|
NextSource Materials Inc
TO:NEXT
|
Canada | CA$62.73 Million |
|
Ssangyong Information & Communications Corp
KQ:010280
|
Korea | ₩203.54 Billion |
|
Fuel Tech Inc
NASDAQ:FTEK
|
USA | $5.83 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Yuhan Corp Preferred's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Yuhan Corp Preferred (000105) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Yuhan Corp Preferred's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Yuhan Corp Preferred (2014–2025)
The table below shows the annual total liabilities of Yuhan Corp Preferred from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩858.64 Billion ≈ $581.89 Million |
+8.50% |
| 2024-12-31 | ₩791.38 Billion ≈ $536.31 Million |
+88.70% |
| 2023-12-31 | ₩419.38 Billion ≈ $284.21 Million |
-9.80% |
| 2022-12-31 | ₩464.92 Billion ≈ $315.07 Million |
-11.93% |
| 2021-12-31 | ₩527.92 Billion ≈ $357.77 Million |
-3.49% |
| 2020-12-31 | ₩547.02 Billion ≈ $370.71 Million |
+17.08% |
| 2019-12-31 | ₩467.21 Billion ≈ $316.62 Million |
-10.51% |
| 2018-12-31 | ₩522.08 Billion ≈ $353.80 Million |
+6.91% |
| 2017-12-31 | ₩488.35 Billion ≈ $330.95 Million |
-11.11% |
| 2016-12-31 | ₩549.39 Billion ≈ $372.31 Million |
+6.39% |
| 2015-12-31 | ₩516.39 Billion ≈ $349.95 Million |
+51.83% |
| 2014-12-31 | ₩340.11 Billion ≈ $230.49 Million |
-- |
About Yuhan Corp Preferred
Yuhan Corporation operates as a pharmaceutical company in South Korea and internationally. It offers manufacturing services, such as custom manufacturing; process research and development of active pharmaceutical products (APIs) and intermediates; kilo and pilot-scale production of APIs and intermediates; commercial production of APIs and intermediates; production of chemical specialties; and ana… Read more